Cancer Immunology Miniatures

Therapeutic In Situ Autovaccination against Solid Cancers

with Intratumoral Poly-ICLC:

Case Report, Hypothesis, and Clinical Trial

Andres M. Salazar¹, Rodrigo B. Erlich², Alexander Mark³, Nina Bhardwaj⁴,

Ronald B Herberman¹*

1) Oncovir, Inc., Washington, DC 2) Bay Hematology-Oncology, Easton, MD 3) Bethesda MRI, Bethesda, MD, 4) Icahn School of Medicine at Mt. Sinai, NY. *deceased

Running Title: In Situ Cancer Autovaccination with Intratumoral Poly-ICLC

Key Words: Poly-ICLC, Hiltonol, intratumoral, autovaccination, solid cancers, sarcoma

Research Support. This work was supported in part by a grant from the Cancer Research Institute, NY, NY. Oncovir, Inc. provided Hiltonol® (poly-ICLC).

Correspondence: Andres M Salazar, MD: asalazar@starpower.net

Oncovir, Inc
3203 Cleveland Ave, NW
Washington, DC, 20008
202-342-1726

Potential Conflicts: AM Salazar and A Mark own stock in Oncovir, Inc

Number of words: 1,920; 3 figures
Pathogen-associated molecular patterns (PAMPs) are standalone innate and adaptive immunomodulators and critical vaccine components.

We present a strategy of sequential intratumoral (IT) and intramuscular (IM) injections of the stabilized dsRNA viral mimic and PAMP, poly-inosinic-polycytidylic acid-poly-lysine-carboxymethylcellulose (poly-ICLC, Hiltonol®). We report the first treated patient, a young man with an exceptionally advanced facial embryonal rhabdomyosarcoma with extension to the brain. Following treatment, the patient showed tumor inflammation consistent with immunotherapy, followed by gradual, marked tumor regression, with extended survival.

Sequential IT and IM Poly-ICLC injections mimicking a viral infection can induce an effective, in situ, personalized systemic therapeutic ‘autovaccination’ against a patient’s tumor antigens. We postulate a three-step immunomodulatory process: 1) Innate-immune local tumor-killing induced by IT poly-ICLC; 2) Activation of dendritic cells with T-helper 1 (Th1) cell- and cytotoxic T lymphocyte (CTL)-weighted priming against the released tumor antigens; and 3) IM Poly-ICLC maintenance of the systemic antitumor immune response via chemokine induction, facilitation of CTL killing through the induction of costimulators such as OX40, inflammasome activation, and increase in the T-effector/Treg (regulatory T cell) ratio. These results support the use of certain simple and inexpensive IT PAMPs to favorably stimulate effective immunity against solid cancers. A phase II clinical trial testing the hypothesis presented has begun accruals. (clinicaltrials.gov, NCT01984892)
Introduction

Pathogen-associated molecular patterns (PAMPs) are standalone innate and adaptive immunomodulators or ‘danger signals’, and essential vaccine components. Polyinosinic-Polycytidylic acid-polyllysine-carboxymethylcellulose (poly-ICLC, Hiltonol®) is a stabilized double-stranded RNA (dsRNA), which is a viral mimic, a ligand to toll-like receptor 3 (TLR3), and a PAMP. We present a strategy of sequential intratumoral (IT) and intramuscular (IM) injections of Hiltonol that can induce a personalized therapeutic ‘autovaccination’ against a patient’s individual tumor antigens, as processed in situ. We report the first case so treated, a patient with very advanced embryonal rhabdomyosarcoma, who is in hospice. The especially encouraging results support the use of certain IT PAMPs to favorably stimulate effective immunity against some advanced cancers. A solid-cancer clinical trial testing this hypothesis has been initiated.

Materials and Methods

In the advanced, compassionate-use case presented, Hiltonol (1 mg) was given IT twice weekly for four weeks followed by a two-week rest period. In the subsequent two cycles, some injections had to be skipped or were given IM.

In the ongoing clinical trial, 1 mg. Hiltonol is given IT thrice weekly for 2 weeks, followed by IM Hiltonol boosters twice weekly for six weeks. A second cycle is followed by a 6-week no-treatment period with evaluation of response at week 26.

Case Report and Results:

The patient was an 18 year-old man with an exceptionally large malignant embryonal rhabdomyosarcoma, who failed eight different regimens of chemotherapy, including pazopanib,
and imetelstat, as well as radiation and proton-beam therapy, and was on hospice. In the months prior to his volunteering for IT Hiltonol treatment approved under compassionate-use exemption, his tumor grew exponentially from his left cheek to fill and grow out of his mouth, expand to his left sinuses, nasal cavity, nasopharynx, left orbit, temporalis muscle, and into the brain. It involved most of his temporal lobe with extension to the frontal lobe, obliteration of the left lateral ventricle and a marked mass effect with compromise of the left cerebral peduncle (Figures 1 and 2). He required a tracheostomy and gastric tube feeding. The mouth and cheek tumor became necrotic by week two of the first treatment cycle. (Fig 2b). Left internal maxillary artery embolization was performed to control bleeding on week 3. The brain tumor also appeared on MRI to be necrotic and on week 4 he was started on bevacizumab (Avastin) q 3 weeks to help control brain swelling.

Formal immunomonitoring was not possible, but the patient developed marked local tumor inflammation after the first IT injection of his second cycle on week 7, prompting a brief course of dexamethasone. Local facial tumor inflammation was also observed after each subsequent injection of IM Hiltonol in the thigh, suggesting the induction of a systemic immune response (Fig 2c). By week 7, the tumor in his mouth appeared largely gone; he was able to eat soup and solid foods, and begin returning to normal activities (Fig 2c). The third cycle was interrupted after two weeks by recurrent infections associated with the large amounts of tumor necrosis, but he recovered and graduated high school on week 21. Pazopanib had been restarted on week 17 and Avastin was discontinued after week 18. He received 2 additional IT injections and 3 IM injections of Hiltonol between weeks 21 and 25 with continued decrease in facial tumor. By week 25, the facial, oral and retro-orbital tumor appeared largely gone or inactive on positron emission tomography (PET), with mainly healing normal structures upon gross inspection (Figs 1f, 3). The large cerebral mass also appeared necrotic on MRI and was negative on PET (Figs 1c and 3). However, there was still significant mass effect and, unfortunately, decompression craniotomy was postponed. He died suddenly with cardiorespiratory arrest on week 27 while being discharged.
from a brief hospitalization for treatment of an infection. Cerebral herniation or pulmonary embolus was suspected, but autopsy was declined.

**Discussion and Hypothesis:**

Immunotherapy is emerging as a major breakthrough in cancer management, concomitant with an increased understanding of basic immunology, tumor evasions and checkpoints, and recognition of the importance of the ‘danger signal’ provided by PAMPs (1). Most cancer vaccines use one or more exogenous tumor-associated antigens, but the ‘host-targeted’ strategy described here attempts to immunize against the patient’s own tumor antigens *in situ*, and is not only theoretically applicable to various histologic tumor types but may also generate a more effective ‘natural’ response to those antigens. Although the present case was complicated by the exceptional size of the tumor, intercurrent infections and other treatments, it nevertheless provides encouraging evidence of the potential for relatively simple, safe and inexpensive immunotherapies. However, the patient’s eventual death due to suspected cerebral herniation and in spite of apparent necrosis of the exceptionally large cerebral lesion is a cautionary note regarding management of such cases.

Poly-ICLC, (Hiltonol®), is a ‘reliable and authentic’ viral mimic and PAMP that at low doses in humans up-regulates several hundred genes closely paralleling the pattern induced by a yellow fever live-virus vaccine, and representing some 10 canonical innate immune pathways (2-4). This includes the induction of a ‘natural mix’ of interferons (IFN), other cytokines and chemokines, activation of natural killer (NK) cells, T cells, myeloid dendritic cells (mDCs) via melanoma differentiation-associated protein 5 (MDA5), TLR3, retinoic acid-inducible gene 1 (RIG-I) helicase, 2′5′oligoadenylate synthetase (OAS), the P68 protein kinase (PKR), and other dsRNA-dependent host defense systems, culminating in a broad innate antitumor and antiviral effect as well as a potent adjuvant effect, with inflammasome and other signaling (5). Poly-ICLC thus
provides the dsRNA ‘danger signal’ normally furnished by viral replication but that has been missing from many modern vaccines for cancer, HIV, malaria, and other diseases. In other words, when properly paired with antigens, Poly-ICLC can generate a 'live-virus vaccine-equivalent' with a comprehensive immune response that includes activation of mDCs and NK cells, processing of relevant antigens, generation of a polyfunctional Th1- and CTL-weighted response, homing to tumor or pathogen via induction of specific chemokines, and facilitation of CTL function through induction of costimulators such as OX40 (6-8). Importantly, the role of dsRNAs such as Poly-ICLC may be bimodal: beginning with induction of IFNs and of dsRNA-dependent systems, and followed by their secondary activation by the dsRNA. Thus, two or more doses of Poly-ICLC at a 24-48 hour interval or pretreatment with IFN can markedly boost antiviral and antitumor activity, perhaps by better mimicking a natural infection (9,10). This is also the dosing regimen used successfully in clinical glioma and in preclinical antiviral studies, as well as in the strategy presented here (5,11-13).

Variations on the ‘autovaccination’ strategy have included the combination of radiotherapy or chemotherapy to induce antigen release, with immunostimulants or oncolytic virus to induce an immune response (14-18). This approach is based on the hypothesis that IT administration of a PAMP will reverse DC inhibition in the treated tumor micro-environment, increase the efficiency of antigen presentation to CTLs, and prevent tolerization to tumor antigens. Such tolerization can be a counterproductive consequence of traditional chemotherapy or radiotherapy that induces release of tumor-associated antigens in the absence of a proper ‘danger signal’ (14).

We postulate that the strategy presented here involves a three-step process. First, IT Hiltonol activates NK cells, various cytokines, TLR3, and other pro-apoptotic mechanisms, resulting in early tumor killing and antigen release (19-21). This may be the mechanism that led to the early
local necrosis in the case reported here. This necrosis was observed before embolization or treatment with Avastin, although the latter may have contributed to the subsequent immune response. Second, in the same local context, Hiltonol recruits and activates mDCs and macrophages at the tumor site, where they acquire tumor antigens that are released, present them to CD4⁺ helper cells and cross-present them to CD8⁺ T cells in the tumor or in the regional lymph nodes to generate antigen-specific CTLs. The repeated administration of the PAMP danger signal IT in the context of the patient's own tumor antigens and in a way that mimics a natural viral infection has also been used successfully with intratumoral CpG and may be critical to this step (15,17,22). Timed release or structured formulations of Poly-ICLC could even better mimic a viral infection, especially for deep tumors where repeated IT administration is logistically more challenging. At the same time, the possibility of overstimulation with PAMP must be considered, and optimal dose and schedule remains uncertain.

The third step is remote targeting and maintenance of antigen-specific CTLs via various poly-ICLC-induced chemokines, costimulatory factors and other mechanisms (8). This activity directed at the local tumor microenvironment was perhaps illustrated by the local tumor inflammation in response to each remote IM injection of poly-ICLC in the reported case. Such inflammation with a gradual tumor response is typical of some immunotherapies (23). Murine sarcoma and lymphoma studies have demonstrated similar activity of IT Poly-ICLC or the TLR9 agonist CpG respectively, including at remote metastases, and especially when combined with anti-CTLA4 and agonist anti-OX40, which boost T-cell responses (15,17,24). Others have demonstrated that poly-IC alone is sufficient to induce expression of the co-stimulatory molecules B7-H2, CD40, and OX40 (25). OX40 in particular may down regulate CTLA4, decrease tumor-specific regulatory T cells (Tregs), increase the T-effector/Treg ratio, and enhance CTL action in the tumor and metastases, and particularly with IT injection of a single target lesion (22,26,27). The dsRNA-dependent PKR induced by Poly-ICLC will also activate the inflammasome pathway (2,28). We thus expect that
continued administration of Poly-ICLC IM after optimal priming will facilitate and maintain sensitized CTL killing in the tumor microenvironment of both the injected and remote metastatic lesions. Clinical support for the concept of post-prime maintenance with IM Poly-ICLC or IT CpG alone also comes from recent successful glioma, lymphoma, and hepatoma trials (13,17; A. de la Torre, manuscript in preparation). Exogenous Avastin, OX40, anti-CTLA4, anti-PD-L1, FLT3L and other costimulatory factors could further synergize with poly-ICLC and enhance this effect. Finally, poly-ICLC boosting can also enhance memory cell longevity (29).

A multicenter adaptive design two-stage Phase II clinical study has begun in patients with the following advanced, unresectable metastatic solid tumors: sarcomas; melanoma; squamous cell skin cancer; and head and neck cancers (clinicaltrials.gov, NCT01984892). In each treatment cycle, one accessible tumor site is targeted for IT injections of 1 mg. Hiltonol thrice weekly for 2 weeks, followed by IM Hiltonol boosters twice weekly for six weeks. A second cycle is followed by a 6-week no-treatment period with evaluation of response at week 26, in the relative absence of inflammation. The primary endpoint is disease control at 26 weeks, as defined by the Immune-Related Response Criteria (irRC; ref. 23). Secondary objectives are overall survival and immunologic response in blood and tissue biopsies, including immunoscore.

In summary, we present results from a complicated case suggesting that sequential IT plus IM Hiltonol (poly-ICLC) can have a dramatic antitumor effect. We hypothesize that this in situ autovaccination strategy comprises three immunomodulatory steps. The first step is the innate immune local tumor killing induced by intratumoral Hiltonol. A close second step is Th1- and CTL-weighted priming through the repeated in situ combination of the Hiltonol danger signal with the tumor antigens released in step 1 and further processed and cross-presented by Hiltonol-activated mDC. The third step is maintenance of the systemic antitumor immune response and
migration of antitumor CTLs to remote metastases, through repeated IM Hiltonol induction of
chemokines, OX40 and other costimulatory factors, as well as inflammasome activation.
Exogenous costimulators or checkpoint blockers may enhance this action. An ongoing clinical trial
in solid cancer patients will further clarify these findings.
Author Disclosures:

Employment or Leadership Position: Andres M. Salazar, Ronald B. Herberman: Oncovir

Stock Ownership: Andres M. Salazar, Alexander Mark: Oncovir, Inc.

Honoraria: None

Research Funding: None. Other Remuneration: None

Author Contributions:

Conception and design: Andres M. Salazar, Ronald B. Herberman, Nina Bhardwaj, Rodrigo Erlich

Provision of study materials or patients: Rodrigo Erlich, Andres M Salazar.

Acquisition of Data, Study supervision: Rodrigo Erlich

Analysis and interpretation of Data: Rodrigo Erlich, Andres M. Salazar, Ronald Herberman, Alexander Mark, Nina Bhardwaj

Manuscript writing: Andres M. Salazar, Ronald B. Herberman, Nina Bhardwaj

Final approval of manuscript: All Authors.
References


Acknowledgements:

We thank the patient and his family, whose courage, motivation, and keen, meticulous observations played a critical role in his treatment and in refinement of the strategy presented here. This work was supported in part by a grant from the Cancer Research Institute, New York. Oncovir, Inc. provided Hiltonol®.

Figure Legends

Figure 1. A-C: Axial Flair MRI on weeks 2, 9, and 24; showing massive intracranial tumor with vasogenic edema compressing the left cerebral peduncle, decreasing by week 9. Fig 1 C on week 24 shows signal void corresponding to gas post necrosis and new mass effect on the suprasellar cistern.

Figure 1 D-F: Axial Contrast MRI on weeks 2, 9, and 24 showing massive enhancing tumor in the left masticator space, with necrosis and decreased enhancement by week 9. Fig. 1 F on week 24 shows extensive necrosis with marked decrease in the size of tumor, signal void with cutaneous fistula, and reduced patchy enhancement. (The patient had not undergone surgery.)

Figure 2. A-D: Patient 6 weeks pre-treatment and at post-treatment weeks 2, 7, and 21

Figure 3. Positron emission tomography at week 24 showing decreased uptake in both facial and intracranial tumor. Marginal uptake could represent active tumor or inflammation.
Figure 1

A) Flair MRI, Day 14  
B) Flair MRI, Wk 9  
C) Flair MRI Week 24  

D) Contrast MRI, Day 14  
E) Contrast MRI, Wk 9  
F. Contrast MRI Week 24
Figure 2

A) 6 Week pre-treatment  B) Week 2 Post Treatment.  C) Week 7  D) Week 21
Figure 3
Cancer Immunology Research

Therapeutic In-Situ Autovaccination against Solid Cancers with Intratumoral Poly-ICLC: Case report, Hypothesis, and Clinical Trial

Andres M. Salazar, Rodrigo B Erlich, Alexander Mark, et al.

Cancer Immunol Res  Published OnlineFirst May 6, 2014.

Updated version  Access the most recent version of this article at:
doi:10.1158/2326-6066.CIR-14-0024

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.